Gastric Cancer Registry for Epidemiology and Molecular Risk Factor

Gastric Cancer Clinical Trial

Official title:

Analysis and Prediction of Epidemiology and Molecular Biologic Risks of Gastric Cancer by Multicenter Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03046745
• Other study ID #: KNUMC 2016-07-014
• Status: Recruiting
• Start date: August 2016
• Est. completion date: April 2022

Study information

• Verified date: May 2020
• Source: Kyungpook National University Hospital
• Contact: Seong Woo Jeon, Professor
• Phone: +82-53-200-3089
• Email: sw-jeon[@]hanmail.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a multi-center, prospective cohort study which are planned to enroll the 2,500 patients who diagnosed the primary gastric cancer and 5,000 healthy normal cohort participants for 5 years. All participants who enrolled in this registry, the participants were questioned by the gastric cancer survey and the serum and tissue of these participants were analyzed.

The main aim of this study is

1. To evaluate the optimal interval of endoscopic screening for early detection of gastric cancer and risk factors in Korean.

2. To evaluate the diagnostic validity of serum biomarker (combining pepsinogen, H pylori IgG Antibody, and TFF3) as a screening test for detection of GC in Korean.

Description:

Gastric cancer (GC) is the fourth most common type of cancer (934 000 new cases, 8.6% of all new cancer cases in 2002), and the second most common cause of cancer death (700 000 deaths annually) in the world. Several Asian countries, including China, Japan, and Korea, have the highest incidences of GC in the world. Because the prognosis of early GC is highly favorable, high- prevalence countries, such as Japan and Korea, have sought to reduce the disease burden by providing GC screening to aver- age-risk populations. In Korea, national GC screening was instituted in 1999 as part of the National Cancer Screening Program (NCSP). The NCSP recommends biennial GC screening for males and females older than 40 years of age, using direct or indirect upper gastrointestinal series (UGIS) or endoscopy. Upper gastrointestinal endoscopies are generally accepted as the gold standard for the diagnosis and clinicopathological evaluation of GC. Endoscopic examination has been predominantly used to screen symptomatic individuals, and to distinguish patients with GC from those with comparatively benign diseases, such as peptic ulcers. However, there was no consensus for optimal timing of screening endoscopy to detect of early GC.

Thus, investigators are planned to evaluate the optimal endoscopic interval to find early gastric cancer by use of survey between newly diagnosed GC cohort group and healthy control cohort group. In addition, investigators are going to analyze the risk factors of GC in Korean (epidemiologic, diet, and clinical factors). In this study, the investigators are going to enroll the participants who were diagnosed GC and normal control group people, from October 2016 to October 2021 in multi-center, prospectively. The baseline characteristics of the participants, H. pylori status, stage of gastric cancer at diagnosis, treatment modalities, treatment response and mortality were analyzed.

Although diagnosis of gastric cancer has been characterized by endoscopy, there has been a strong demand for serologic marker because accessibility, invasiveness, discomfort of endoscopy. In recent years, there have been advancements in the molecular biomarkers utilized in the cancer detection and in the development of therapeutic agents based on the target genes for a few types of solid tumours excluding GC. With the advancement of molecular biological techniques in the last decades, researchers have gained important insights into the oncogenesis mechanisms of GC. Besides the well-known pathogenic factor, Helicobacter pylori, various experimental approaches have identified oncogenes and tumour suppressor genes, including cell cycle regulation genes in the growth and signal transduction pathways. Recently, several studies were reported about the efficacy of the serum biomarker (serum PG, H. pylori Ig G Antibody and TFF3, etc) for diagnosis of GC. In this present study, investigators are going to the efficacy of serum biomarker by the use of serum of GC patients and health control group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9000
• Est. completion date: April 2022
• Est. primary completion date: April 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patients who were diagnosed of primary gastric adenocarcinoma and drew up agreement for understanding and enrollment of this study.

Exclusion Criteria:

• Being treated (surgery, endoscopic resection and chemoradiation) after the diagnosis of gastric cancer; metastatic gastric cancer; refusal to participation of this study

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	Seong Woo Jeon	Daegu

Sponsors (2)

Lead Sponsor	Collaborator
Kyungpook National University Hospital	Ministry of Health & Welfare, Korea

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (8)

Dhillon PK, Farrow DC, Vaughan TL, Chow WH, Risch HA, Gammon MD, Mayne ST, Stanford JL, Schoenberg JB, Ahsan H, Dubrow R, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Family history of cancer and risk of esophageal and gastric cancers in the United Stat — View Citation

Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991 Jun 1;302(6788):1302-5. — View Citation

Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 Sep;49(3):347-53. Review. — View Citation

Iijima K, Koike T, Abe Y, Ara N, Uno K, Imatani A, Ohara S, Shimosegawa T. Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication. J Gastroenterol. 2009;44(8):819-25. doi: 10.1007/s00535-00 — View Citation

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 May;150(5):1113-1124.e5. doi: 10.1053/j.gastro.20 — View Citation

Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, Yim JY, Kim HU, Baik GH, Seo GS, Shin JE, Joo YE, Kim JS, Jung HC. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol. 2013 — View Citation

Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study. Cancer Sci. 2003 Jun;94(6):540-7. — View Citation

Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct 17;325(16):1127-31. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval		Up to 5 years
Secondary	The diagnostic validity of serum biomarker (serum pepsinogen and TFF3) for detection of gastric cancer		up to 5 years
Secondary	Analysis of proportion of each treatment of gastric cancer and 5 year survival	Investigators should analyze the treatment patterns (endoscopic resection, surgery, chemotherapy or supportive care) of gastric cancer and assess the survival rate according to each treatment modalities.	up to 10 years
Secondary	Analysis of quality of life questionnaire after early gastric cancer between endoscopic treatment group and surgery group	Investigators should measure QOL of the enrolled patients with EORTC questionnaire and compare the changing trends in each groups, prospectively.	up to 6 years
Secondary	the incidence of gastric cancer development in control group		up to 20 years
Secondary	the incidence of metachronous gastric neoplasm after endoscopic treatment or surgery		up to 10 years
Secondary	Analysis of clinical differences and characteristics between positive gastric cancer family history and negative family history groups		up to 5 years
Secondary	Stage, treatment and prognosis of gastric cancer according to molecular classification		up to 10 years
Secondary	Stage, treatment and prognosis of gastric cancer according to endoscopic screening interval		up to 10 years
Secondary	Reservation of frozen serum for novel gastric cancer serologic marker analysis		up to 5 years